Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia
Launched by ALLERGAN · Jul 21, 2014
Trial Information
Current as of June 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • -Presbyopia in each eye that impacts daily activities.
- Exclusion Criteria:
- • Use of any topical ophthalmic medications, including artificial tears
- • Contact lens use in either eye within 14 days or planned use during the study
- • History of eye surgery
- • Diagnosis of any type of glaucoma or ocular hypertension
About Allergan
Allergan, a global leader in pharmaceutical innovation, specializes in developing and commercializing a diverse portfolio of advanced therapeutic and aesthetic products. With a commitment to improving the health and well-being of patients, Allergan conducts rigorous clinical trials to evaluate the safety and efficacy of its therapies across various medical fields, including ophthalmology, dermatology, and neuroscience. The company is dedicated to adhering to the highest ethical standards and regulatory guidelines, ensuring that its research not only advances medical science but also meets the needs of healthcare providers and patients worldwide. Through strategic collaborations and a focus on scientific excellence, Allergan continues to drive advancements in treatment options and enhance patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Newport Beach, California, United States
Patients applied
Trial Officials
Medical Director
Study Director
Allergan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials